Triptans

Congenital heart defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3510
R6891		 Spielmann (Control mainly exposed other treatments, sick), 2017 Congenital heart defects during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.19 [0.04;0.86] C
excluded (control group) 		2/364   12/429 14 364
ref
S3509
R6867		 Spielmann (Control unexposed, disease free), 2017 Congenital heart defects during pregnancy (anytime or not specified) excluded prospective cohort unexposed, disease free Adjustment: No 0.49 [0.11;2.12] C
excluded (exposition period) 		2/364   17/1,520 19 364
ref
S3594
R7294		 De Jonge - Sumatriptan, 2013 Heart defects 1st trimester case control unexposed (general population or NOS) Adjustment: No 2.31 [0.84;6.39] C 4/62   869/30,034 873 62
ref
S3494
R6814		 Källén (control exposed to ergots), 2011 Any cardiovascular defect 1st trimester population based cohort propective exposed to other treatment, sick excluded Adjustment: No 0.78 [0.34;1.80] C
excluded (control group) 		29/2,777   7/527 36 2,777
ref
S849
R6809		 Källén (control unexposed, disease free), 2011 Any cardiovascular defect 1st trimester population based cohort propective unexposed, disease free Adjustment: Yes 1.00 [0.69;1.44] 29/2,777   12,805/1,229,901 12,834 2,777
ref
Total 2 studies 1.32 [0.61;2.88] 13,707 2,839
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF De Jonge - Sumatriptan, 2013De Jonge - Sumatriptan, 2013 2.31[0.84; 6.39]8736233%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Källén (control unexposed, disease free), 2011Källén, 2011 1 1.00[0.69; 1.44]12,8342,77767%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 57% 1.32[0.61; 2.88]13,7072,8390.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: control unexposed, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.00[0.69; 1.44]12,8342,777 -NAKällén (control unexposed, disease free), 2011 1 case control studiescase control studies 2.31[0.84; 6.39]87362 -NADe Jonge - Sumatriptan, 2013 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.32[0.61; 2.88]13,7072,83957%NADe Jonge - Sumatriptan, 2013 Källén (control unexposed, disease free), 2011 2 Tags Adjustment   - No  - No 2.31[0.84; 6.39]87362 -NADe Jonge - Sumatriptan, 2013 1   - Yes  - Yes 1.00[0.69; 1.44]12,8342,777 -NAKällén (control unexposed, disease free), 2011 1 All studiesAll studies 1.32[0.61; 2.88]13,7072,83957%NADe Jonge - Sumatriptan, 2013 Källén (control unexposed, disease free), 2011 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 3494, 3510

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.32[0.61; 2.88]13,7072,83957%NADe Jonge - Sumatriptan, 2013 Källén (control unexposed, disease free), 2011 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.78[0.34; 1.80]362,777 -NAKällén (control exposed to ergots), 2011 10.510.01.0